Cardiorenal syndrome and diabetes: an evil pairing

Area of Science:

• Cardiology
• Nephrology
• Endocrinology
• Pharmacology

Background:

• Cardiorenal syndrome (CRS) describes the interconnected dysfunction of the heart and kidneys.
• Diabetes mellitus (DM) significantly increases the risk of heart failure (HF) and chronic kidney disease (CKD), a leading cause of kidney failure.
• The combination of CRS and DM is linked to higher hospitalization and mortality rates.

Purpose of the Study:

• To highlight the challenges in managing patients with cardiorenal syndrome and diabetes mellitus.
• To discuss the evolving therapeutic landscape for cardiorenal patients.
• To emphasize the role of multidisciplinary care and novel pharmacological agents.

Main Methods:

• Review of current literature on cardiorenal syndrome, diabetes mellitus, and related treatments.
• Analysis of the impact of sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
• Discussion of the benefits of specialized cardiorenal units and multidisciplinary teams.

Main Results:

• SGLT2 inhibitors demonstrate cardiovascular benefits in patients with type 2 DM, CKD, and HF, offering a new therapeutic avenue for CRS.
• GLP-1 RAs have shown cardiovascular benefits and reduced CKD progression in patients with DM and cardiovascular disease.
• Integrated care models and new drug classes are improving management of cardio-renal-metabolic conditions.

Conclusions:

• The interplay between the heart, kidneys, and diabetes necessitates a comprehensive management approach.
• Novel pharmacotherapies, including SGLT2 inhibitors and GLP-1 RAs, represent significant advancements in treating cardiorenal syndrome.
• Multidisciplinary cardiorenal units are crucial for optimizing holistic patient care and outcomes.